000 01391 a2200409 4500
005 20250518091716.0
264 0 _c20200909
008 202009s 0 0 chi d
022 _a0253-3758
024 7 _a10.3760/cma.j.cn112148-20200308-00171
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aShi, H Z
245 0 0 _a[2019 novel coronavirus, angiotensin converting enzyme 2 and cardiovascular drugs].
_h[electronic resource]
260 _bZhonghua xin xue guan bing za zhi
_cJul 2020
300 _a532-538 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAngiotensin Receptor Antagonists
650 0 4 _aAngiotensin-Converting Enzyme 2
650 0 4 _aBetacoronavirus
650 0 4 _aCOVID-19
650 0 4 _aCardiovascular Agents
_xpharmacology
650 0 4 _aCardiovascular Diseases
650 0 4 _aCoronavirus Infections
_xphysiopathology
650 0 4 _aHumans
650 0 4 _aPandemics
650 0 4 _aPeptidyl-Dipeptidase A
_xphysiology
650 0 4 _aPneumonia, Viral
_xphysiopathology
650 0 4 _aSARS-CoV-2
700 1 _aMa, P
700 1 _aGao, F Y
700 1 _aChen, G L
700 1 _aWang, Y H
700 1 _aXian, X D
700 1 _aDong, E D
773 0 _tZhonghua xin xue guan bing za zhi
_gvol. 48
_gno. 7
_gp. 532-538
856 4 0 _uhttps://doi.org/10.3760/cma.j.cn112148-20200308-00171
_zAvailable from publisher's website
999 _c30737247
_d30737247